How many drugs treat Ventricular Arrhythmia?

Drug Landscape tracks 7 marketed treatments for Ventricular Arrhythmia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Ventricular Arrhythmia?

Most recent: Mexitil — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/ventricular-arrhythmia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ventricular Arrhythmia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ventricular Arrhythmia (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Ventricular Arrhythmia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Bretylium Tosylate	BRETYLIUM	Pfizer	bretylium	Beta-1 adrenergic receptor	1986-01-01
Mexitil	MEXILETINE	Boehringer Ingelheim	Antiarrhythmic	5-hydroxytryptamine receptor 2B	1985-01-01
Norpace Cr	DISOPYRAMIDE	Pfizer	Antiarrhythmic	Histamine H1 receptor	1977-01-01
Lignospan Forte	Lidocaine Hydrochloride	Fresenius Kabi	local anesthetic, amide type	neuronal membrane ionic channels	1948-01-01
Lignocaine	Lignocaine	University of Malaya		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Lidocain	Lidocain	Bayer		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
xylocain	xylocain	Saint-Joseph University		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-23 — Mexitil · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 6 drugs in Ventricular Arrhythmia
Pfizer · 2 drugs in Ventricular Arrhythmia
Boehringer Ingelheim · 1 drug in Ventricular Arrhythmia
Saint-Joseph University · 1 drug in Ventricular Arrhythmia
University of Malaya · 1 drug in Ventricular Arrhythmia
Fresenius Kabi · 1 drug in Ventricular Arrhythmia
Bayer · 1 drug in Ventricular Arrhythmia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Ventricular Arrhythmia:

Cite this brief

Drug Landscape (2026). Ventricular Arrhythmia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/ventricular-arrhythmia. Accessed 2026-06-10.

Ventricular Arrhythmia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing